PreveCeutical Medical (TSE:PREV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Dr. Barry Ticho to its Scientific Advisory Board, leveraging his seasoned expertise in drug development and biotechnology. Dr. Ticho’s impressive career includes leadership roles at Stoke Therapeutics and contributions to companies like Verve and Moderna, marking significant advancements in treating various diseases. This strategic appointment is expected to enhance BioGene’s initiatives in developing innovative therapies.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.